Journal
DRUG DISCOVERY TODAY
Volume 17, Issue 13-14, Pages 774-783Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2012.03.007
Keywords
-
Categories
Funding
- BioDeakin, ITRI, Deakin University
- University of Melbourne, Australia
- Punjabi University, India
- Indo-Swiss Joint Research Program (ISJRP) Scholarship
- Australian Research Council (ARC)
Ask authors/readers for more resources
Ribosome-inactivating proteins (RIPs) are mainly present in plants and function to inhibit protein synthesis through the removal of adenine residues from eukaryotic ribosomal RNA (rRNA). They are broadly classified into two groups: type I and type II. Type I RIPs are a diverse family of proteins comprising a single polypeptide chain, whereas type II RIPs are heterodimeric glycoproteins comprising an A-chain (functionally equivalent to a type I RIP) linked via a disulphide bond to a B chain, mediating cell entry. In this review, we describe common type I and type II RIPs, their diverse biological functions, mechanism of cell entry, stability in plasma and antigenicity. We end with a discussion of promising applications for RIPs in biomedicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available